Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Trastuzumab Rezetecan in Triple Negative Breast Cancer: NCT07760844 Clinical Landscape Report 2026
9 min read
Trastuzumab Rezetecan in Triple Negative Breast Cancer: NCT07760844 Clinical Landscape Report 2026
11 September 2026
NCT07760844 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Apatinib Mesylate in Metastatic Pancreatic Cancer: NCT07802184 Clinical Landscape Report 2026
9 min read
Apatinib Mesylate in Metastatic Pancreatic Cancer: NCT07802184 Clinical Landscape Report 2026
11 September 2026
NCT07802184 clinical landscape for Metastatic Pancreatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Zasocitinib in Pustulosis of Palms and Soles: NCT07752108 Clinical Landscape Report 2026
9 min read
Zasocitinib in Pustulosis of Palms and Soles: NCT07752108 Clinical Landscape Report 2026
11 September 2026
NCT07752108 clinical landscape for Pustulosis of Palms and Soles: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Raludotatug deruxtecan in HRD-positive Ovarian Cancer: NCT07776691 Clinical Landscape Report 2026
9 min read
Raludotatug deruxtecan in HRD-positive Ovarian Cancer: NCT07776691 Clinical Landscape Report 2026
11 September 2026
NCT07776691 clinical landscape for HRD-positive Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
CT0596 CAR-T Cell in Relapse multiple myeloma: NCT07760454 Clinical Landscape Report 2026
9 min read
CT0596 CAR-T Cell in Relapse multiple myeloma: NCT07760454 Clinical Landscape Report 2026
11 September 2026
NCT07760454 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Aritinercept in Myasthenia Gravis: NCT07596901 Clinical Landscape Report 2026
9 min read
Aritinercept in Myasthenia Gravis: NCT07596901 Clinical Landscape Report 2026
11 September 2026
NCT07596901 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
LY4329090 in Obesity: NCT07808073 Clinical Landscape Report 2026
9 min read
LY4329090 in Obesity: NCT07808073 Clinical Landscape Report 2026
11 September 2026
NCT07808073 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Pembrolizumab in Adenocarcinoma of large intestine: NCT07811193 Clinical Landscape Report 2026
9 min read
Pembrolizumab in Adenocarcinoma of large intestine: NCT07811193 Clinical Landscape Report 2026
11 September 2026
NCT07811193 clinical landscape for Adenocarcinoma of large intestine: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
Read →
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07744724 Clinical Landscape Report 2026
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07744724 Clinical Landscape Report 2026
11 September 2026
NCT07744724 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Malignant Mesothelioma of Peritoneum: NCT07510815 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Malignant Mesothelioma of Peritoneum: NCT07510815 Clinical Landscape Report 2026
11 September 2026
NCT07510815 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
AbobotulinumtoxinA (Ipsen Biopharm Ltd) in Basal Cell Carcinoma: NCT07720726 Clinical Landscape Report 2026
9 min read
AbobotulinumtoxinA (Ipsen Biopharm Ltd) in Basal Cell Carcinoma: NCT07720726 Clinical Landscape Report 2026
11 September 2026
NCT07720726 clinical landscape for Basal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
203Pb-RMX-VH-PIB in Glioblastoma Multiforme: NCT07733674 Clinical Landscape Report 2026
9 min read
203Pb-RMX-VH-PIB in Glioblastoma Multiforme: NCT07733674 Clinical Landscape Report 2026
11 September 2026
NCT07733674 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →